Synthetic Biologics Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program
— Company Expects to Initiate C. difficile Clinical Trials in 2014 — ROCKVILLE, Md., June 30, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of […]